In this context, this prospective study aims to: 1) quantify serum GP73 levels in biopsy-proven MASLD and evaluate their correlation with significant fibrosis;2) establish and validate a novel algorithm combining serum GP73 and TE for diagnosis of significant fibrosis in MASLD. The gene discussed is GOLM1; the disease is metabolic dysfunction-associated steatotic liver disease.